London
· Delayed Price · Currency is GBP · Price in USD BioMarin Pharmaceutical Statistics
Total Valuation
LON:0HNC has a market cap or net worth of GBP 8.94 billion. The enterprise value is 8.56 billion.
| Market Cap | 8.94B |
| Enterprise Value | 8.56B |
Important Dates
The next estimated earnings date is Friday, April 25, 2025.
| Earnings Date | Apr 25, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.67% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 179.59M |
Valuation Ratios
The trailing PE ratio is 26.23.
| PE Ratio | 26.23 |
| Forward PE | n/a |
| PS Ratio | 3.92 |
| PB Ratio | 1.98 |
| P/TBV Ratio | 2.18 |
| P/FCF Ratio | 22.97 |
| P/OCF Ratio | 19.54 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.71, with an EV/FCF ratio of 21.99.
| EV / Earnings | 25.11 |
| EV / Sales | 3.99 |
| EV / EBITDA | 16.71 |
| EV / EBIT | 19.95 |
| EV / FCF | 21.99 |
Financial Position
The company has a current ratio of 5.33, with a Debt / Equity ratio of 0.11.
| Current Ratio | 5.33 |
| Quick Ratio | 2.96 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.93 |
| Debt / FCF | 1.30 |
| Interest Coverage | 45.01 |
Financial Efficiency
Return on equity (ROE) is 8.05% and return on invested capital (ROIC) is 5.76%.
| Return on Equity (ROE) | 8.05% |
| Return on Assets (ROA) | 5.15% |
| Return on Invested Capital (ROIC) | 5.76% |
| Return on Capital Employed (ROCE) | 8.93% |
| Revenue Per Employee | 749,876 |
| Profits Per Employee | 112,159 |
| Employee Count | 3,040 |
| Asset Turnover | 0.41 |
| Inventory Turnover | 0.50 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.42% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -32.42% |
| 50-Day Moving Average | 66.86 |
| 200-Day Moving Average | 71.62 |
| Relative Strength Index (RSI) | 47.85 |
| Average Volume (20 Days) | 255 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.73 |
Income Statement
In the last 12 months, LON:0HNC had revenue of GBP 2.28 billion and earned 340.96 million in profits. Earnings per share was 1.76.
| Revenue | 2.28B |
| Gross Profit | 1.82B |
| Operating Income | 455.33M |
| Pretax Income | 432.74M |
| Net Income | 340.96M |
| EBITDA | 532.35M |
| EBIT | 455.33M |
| Earnings Per Share (EPS) | 1.76 |
Balance Sheet
The company has 908.77 million in cash and 506.40 million in debt, giving a net cash position of 402.37 million.
| Cash & Cash Equivalents | 908.77M |
| Total Debt | 506.40M |
| Net Cash | 402.37M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 4.52B |
| Book Value Per Share | 23.69 |
| Working Capital | 2.10B |
Cash Flow
In the last 12 months, operating cash flow was 457.57 million and capital expenditures -68.23 million, giving a free cash flow of 389.33 million.
| Operating Cash Flow | 457.57M |
| Capital Expenditures | -68.23M |
| Free Cash Flow | 389.33M |
| FCF Per Share | n/a |
Margins
Gross margin is 79.67%, with operating and profit margins of 19.97% and 14.96%.
| Gross Margin | 79.67% |
| Operating Margin | 19.97% |
| Pretax Margin | 18.98% |
| Profit Margin | 14.96% |
| EBITDA Margin | 23.35% |
| EBIT Margin | 19.97% |
| FCF Margin | 17.08% |
Dividends & Yields
LON:0HNC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.67% |
| Shareholder Yield | -2.67% |
| Earnings Yield | 3.81% |
| FCF Yield | 4.35% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0HNC has an Altman Z-Score of 7.99.
| Altman Z-Score | 7.99 |
| Piotroski F-Score | n/a |